Thymoglobulin in Cadaver Donor

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the efficacy and Security of Thymoglobuline in cadaveric donor Efficacy: To demonstrate that in cadaveric donor, Thymoglobuline diminished graft alloreactivity by decreasing expression of inflammatory markers in graft biopsies Security:To demonstrate that the administration of Thymoglobulin does not have side effects in renal recipients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Investigación Hospital Universitario La Paz
• Collaborator: Hospital de Santa Maria, Portugal
• Treatments: Thymoglobulin

Criteria

Inclusion Criteria:

• Accepted adults cadaveric donors for renal transplant from University Hospital La Paz( Madrid) and from University Hospital Santa Maria (Lisbon)

• Informed consent from relatives for including in the study

Exclusion Criteria:

• Known allergy to the rabbit proteins

• Non accepted grafts

• Family refusal to consent